Articles Referencing DRTX

An Investment Update On Trius Therapeutics' Tedizolid

8/22/2012, 10:34 am from SeekingAlpha in Investing, Stocks

By Smith On Stocks : Investment Recommendation I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: [[TSRX]]). This note is follow-up to a 35 page report called... Read >>

IPO market heats up with four mid-summer deals, 11 on the calendar

7/20/2012, 5:56 pm from Renaissance Capital in News Headlines, IPOs

The IPO market exhibited strong signs of life this week when four companies were able to price , with three doing so above their initial ranges. Additionally, all four companies are trading... Read >>

Durata Therapeutics prices IPO at $9, below the range

7/18/2012, 7:32 pm from Renaissance Capital in News Headlines, IPOs

Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13.... Read >>

5 US IPOs planned for the week of Jul 16

7/16/2012, 8:00 am from Renaissance Capital in News Headlines, IPOs

The following IPOs are expected to price this week : Durata Therapeutics ( DRTX ), which is developing Phase 3 antibiotic candidate for acute skin infections, plans to raise $75 million... Read >>

Durata Therapeutics sets terms for $75 million US IPO

7/9/2012, 5:14 pm from Renaissance Capital in News Headlines, IPOs

Durata Therapeutics, a acquired rights from Pfizer to a Phase 3 candidate for the treatment of skin infections, announced terms for its IPO on Monday. The Morristown, NJ-based company plans to... Read >>